Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters.

Autor: Collier AY; Beth Israel Deaconess Medical Center, Boston, MA, USA., Miller J; Beth Israel Deaconess Medical Center, Boston, MA, USA., Hachmann NP; Beth Israel Deaconess Medical Center, Boston, MA, USA., McMahan K; Beth Israel Deaconess Medical Center, Boston, MA, USA., Liu J; Beth Israel Deaconess Medical Center, Boston, MA, USA., Apraku Bondzie E; Beth Israel Deaconess Medical Center, Boston, MA, USA., Gallup L; Beth Israel Deaconess Medical Center, Boston, MA, USA., Rowe M; Beth Israel Deaconess Medical Center, Boston, MA, USA., Schonberg E; Beth Israel Deaconess Medical Center, Boston, MA, USA., Thai S; Beth Israel Deaconess Medical Center, Boston, MA, USA., Barrett J; Beth Israel Deaconess Medical Center, Boston, MA, USA., Borducchi EN; Beth Israel Deaconess Medical Center, Boston, MA, USA., Bouffard E; Beth Israel Deaconess Medical Center, Boston, MA, USA., Jacob-Dolan C; Beth Israel Deaconess Medical Center, Boston, MA, USA., Mazurek CR; Beth Israel Deaconess Medical Center, Boston, MA, USA., Mutoni A; Beth Israel Deaconess Medical Center, Boston, MA, USA., Powers O; Beth Israel Deaconess Medical Center, Boston, MA, USA., Sciacca M; Beth Israel Deaconess Medical Center, Boston, MA, USA., Surve N; Beth Israel Deaconess Medical Center, Boston, MA, USA., VanWyk H; Beth Israel Deaconess Medical Center, Boston, MA, USA., Wu C; Beth Israel Deaconess Medical Center, Boston, MA, USA., Barouch DH; Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jazyk: angličtina
Zdroj: BioRxiv : the preprint server for biology [bioRxiv] 2022 Oct 25. Date of Electronic Publication: 2022 Oct 25.
DOI: 10.1101/2022.10.24.513619
Abstrakt: Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.
Databáze: MEDLINE